More than 200 industry leaders have spoken: the 2025 Trends in Specialty Drug Benefits Report, co-sponsored by Genentech and Pharmaceutical Strategies Group (PSG), is here. This executive summary captures how payers are resetting specialty drug strategies and what that means…
Presented by:
